TY - JOUR
T1 - Executive summary of the 12th HHT international scientific conference
AU - Andrejecsk, Jillian W.
AU - Hosman, Anna E.
AU - Botella, Luisa M.
AU - Shovlin, Claire L.
AU - Arthur, Helen M.
AU - Dupuis-Girod, Sophie
AU - Buscarini, Elisabetta
AU - Hughes, Christopher C.W.
AU - Lebrin, Franck
AU - Mummery, Christine L.
AU - Post, Marco C.
AU - Mager, Johannes J.
N1 - Publisher Copyright:
© 2017, Springer Science+Business Media B.V., part of Springer Nature.
PY - 2018/2/1
Y1 - 2018/2/1
N2 - Hereditary hemorrhagic telangiectasia is an autosomal dominant trait affecting approximately 1 in 5000 people. A pathogenic DNA sequence variant in the ENG, ACVRL1 or SMAD4 genes, can be found in the majority of patients. The 12th International Scientific HHT Conference was held on June 8–11, 2017 in Dubrovnik, Croatia to present and discuss the latest scientific achievements, and was attended by over 200 scientific and clinical researchers. In total 174 abstracts were accepted of which 58 were selected for oral presentations. This article covers the basic science and clinical talks, and discussions from three theme-based workshops. We focus on significant emergent themes and unanswered questions. Understanding these topics and answering these questions will help to define the future of HHT research and therapeutics, and ultimately bring us closer to a cure.
AB - Hereditary hemorrhagic telangiectasia is an autosomal dominant trait affecting approximately 1 in 5000 people. A pathogenic DNA sequence variant in the ENG, ACVRL1 or SMAD4 genes, can be found in the majority of patients. The 12th International Scientific HHT Conference was held on June 8–11, 2017 in Dubrovnik, Croatia to present and discuss the latest scientific achievements, and was attended by over 200 scientific and clinical researchers. In total 174 abstracts were accepted of which 58 were selected for oral presentations. This article covers the basic science and clinical talks, and discussions from three theme-based workshops. We focus on significant emergent themes and unanswered questions. Understanding these topics and answering these questions will help to define the future of HHT research and therapeutics, and ultimately bring us closer to a cure.
KW - Activin receptor-like kinase 1 (ALK1)
KW - Arteriovenous malformation
KW - Endoglin
KW - Epistaxis
KW - Hereditary hemorrhagic telangiectasia
KW - HHT
UR - http://www.scopus.com/inward/record.url?scp=85042237834&partnerID=8YFLogxK
U2 - 10.1007/s10456-017-9585-2
DO - 10.1007/s10456-017-9585-2
M3 - Article
AN - SCOPUS:85042237834
SN - 0969-6970
VL - 21
SP - 169
EP - 181
JO - Angiogenesis
JF - Angiogenesis
IS - 1
ER -